The development of phosphatidylinositol ether lipid analogues as inhibitors of the serine/threonine kinase, Akt

Joell J. Gills, Phillip A. Dennis

Research output: Contribution to journalReview articlepeer-review

54 Scopus citations

Abstract

The serine/threonine kinase Akt is a component of the phosphatidylinositol 3′-kinase/Akt signal transduction pathway that is activated by receptor tyrosine kinases, activated Ras and integrins. As Akt regulates many processes crucial to carcinogenesis, and Akt activation has been observed in human cancers, intense efforts are underway to develop Akt inhibitors as cancer therapeutics. Towards this aim, phosphatidylinositol ether lipid analogues (PIAs), which are structurally similar to the products of phosphatidylinositol 3′ -kinase, have been synthesised. PIAs inhibit Akt translocation, phosphorylation and kinase activity. Furthermore, they selectively induce apoptosis in cancer cell lines that depend on Akt for survival. This review will trace the development of PIAs, cover the biological activities of PIAs and discuss future steps and challenges in their development. 2004 Ashley Publications Ltd.

Original languageEnglish (US)
Pages (from-to)787-797
Number of pages11
JournalExpert Opinion on Investigational Drugs
Volume13
Issue number7
DOIs
StatePublished - Jul 2004
Externally publishedYes

Keywords

  • Akt
  • Cancer
  • Phosphatidylinositol ether lipid analogue
  • Pleckstrin homology domain

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'The development of phosphatidylinositol ether lipid analogues as inhibitors of the serine/threonine kinase, Akt'. Together they form a unique fingerprint.

Cite this